Introduction:
This article discusses the importance of considering Good Manufacturing Practice (GMP) standards early in the development of cell therapies. Luděk Sojka, CEO of contract developer and manufacturer SCTbio, emphasizes that small biotechs often underestimate the strictness of GMP manufacturing standards and the need for detailed documentation. He suggests that approaching a Contract Development and Manufacturing Organization (CDMO) early on can help navigate the challenges of implementing GMP processes.
- Companies in early development of cell therapies may be surprised by the strictness of commercial manufacturing standards, particularly GMP criteria.
- Moving from a non-GMP process to a GMP process late in development can be challenging and can result in delays.
- Starting materials for cell therapies can vary, and companies need a robust process to accommodate this variability.
- A close partnership with a CDMO experienced in working with cells is crucial, even if the exact cell type used in the therapy is different.
- Hiring a CDMO with expertise in sourcing starting materials and distributing the product can also be beneficial.
Conclusion:
Early-stage biotechs developing cell therapies should prioritize considering GMP manufacturing standards from the beginning. Partnering with a CDMO early on can help navigate the challenges of implementing GMP processes and ensure a robust and efficient manufacturing process.
